Effect of dapagliflozin combined with metformin on blood glucose and pancreatic β-cell function in elderly type 2 diabetes mellitus patients with poorly glycemic control treated with glimepirido
Objective To observe the effect of dapagliflozin combined with metformin on blood glucose and pancreatic β-cell function in elderly T2DM patients with poorly glycemic control treated with glimepirido.Methods Ninety-six cases of elderly T2DM patients with poorly glycemic control treated with glimepirido admitted to Nanchang Hongdu Hospital of Tradi-tional Chinese Medicine from January 2022 to January 2024 were selected,and they were divided into study group(n=48)and control group(n=48)according to the randomized numerical table method.The study group was treated with dapaglifloz-in combined with metformin,and the control group was treated with metformin,and both groups were treated for 3 months.The blood glucose,pancreatic β-cell function indexes before and after treatment,and adverse reactions were compared between the two groups.Results After 3 months of treatment,FPG,2 hPG levels and HOMA-IR of the two groups were lower than those before treatment,and FINS,2 hCP levels and HOMA-β,MBCI,IGI and OGIS of the two groups were higher than before treatment,FPG,2 hPG levels and HOMA-IR in the study group were lower than those in the control group,FINS,2 hCP levels and HOMA-β,MBCI,IGI,OGIS were higher than those in the control group(P<0.05 or P<0.01).The total incidence of adverse reactions in study group was 10.42%,and the difference was not statistically significant compared with 16.67%in the control group(χ2=0.801,P=0.371).Conclusion For elderly T2DM patients with poorly blood glycemic control treated with glimepiride,the use of dapagliflozin combined with metformin can lower blood glucose levels,improve pancreatic function,without elevating the risk adverse reactions,and has high safety.
Type 2 diabetes mellitus,elderlyDapagliflozinMetforminGlimepirideBlood glucosePancreatic β-cell function
万方数据
维普
